Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Dance Pharma, Aerogen to develop inhaled insulin device

Dance Pharma and Aerogen are planning to develop Dance's inhaled insulin product in an aerosol device based on Aerogen's proprietary OnQ Aerosol Generator technology.

Dance has been granted exclusive worldwide license to Aerogen’s aerosol technology for insulin delivery and the other terms of the agreement were not disclosed.

Dance Pharma CEO John Patton said Dance’s team of inhaled insulin experts considered all potential aerosol technologies worldwide and chose Aerogen’s technology because they are convinced it’s the best, most patient-friendly technology for their first inhaled insulin product.

"Our mission at Dance is to provide inhaled insulin in small, discreet, pain-less, and low cost form to patients throughout the world," Patton said.